Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 389(24): 2256-2266, 2023 Dec 14.
Article
in En
| MEDLINE
| ID: mdl-37870955
Full text:
1
Database:
MEDLINE
Main subject:
Uveal Neoplasms
/
Recombinant Fusion Proteins
/
Antineoplastic Combined Chemotherapy Protocols
/
Melanoma
Limits:
Adult
/
Humans
Language:
En
Journal:
N Engl J Med
Year:
2023
Type:
Article